Immunology of Taenia solium taeniasis and human cysticercosis

Parasite Immunology

Volumn 36, Issue 8, 2014, Pages 388-396

  Garcia, H H ^a,b   Rodriguez, S ^b   Friedland, J S ^c  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^b INSTITUTO NACIONAL DE CIENCIAS NEUROLÓGICAS   (Peru)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cysticercosis; Neurocysticercosis; Parasitic infections; Peru; Seizures; Taenia solium

Indexed keywords

ANIMAL; ANIMAL DISEASE; CYSTICERCOSIS; DISEASE TRANSMISSION; GROWTH, DEVELOPMENT AND AGING; HOST PARASITE INTERACTION; HUMAN; IMMUNOLOGY; LIFE CYCLE STAGE; MEAT; NEUROCYSTICERCOSIS; PARASITIC INFECTIONS; PARASITOLOGY; PATHOLOGY; PERU; REVIEW; SEIZURE; SWINE; SWINE DISEASE; TAENIA SOLIUM; TAENIASIS;

CYSTICERCOSIS; NEUROCYSTICERCOSIS; PARASITIC INFECTIONS; PERU; SEIZURES; TAENIA SOLIUM;

ANIMALS; CYSTICERCOSIS; HOST-PARASITE INTERACTIONS; HUMANS; LIFE CYCLE STAGES; MEAT; SWINE; SWINE DISEASES; TAENIA SOLIUM; TAENIASIS;

EID: 84908484087     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12126     Document Type: Review

References (109)

1. Garcia HH & Del Brutto OH. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005; 4: 653-661.
2. Praet N, Kanobana K, Kabwe C, et al. Taenia solium cysticercosis in the Democratic Republic of Congo: how does pork trade affect the transmission of the parasite? PLoS Negl Trop Dis 2010; 4: e817.
3. Flisser A. State of the art of Taenia solium as compared to Taenia asiatica. Korean J Parasitol 2013; 51: 43-49.
4. Flisser A. Taeniasis and cysticercosis due to Taenia solium. Prog Clin Parasitol 1994; 4: 77-116.
5. Schantz PM. Taenia solium cysticercosis: an overview of global distribution and transmission. In Singh G & Prabhakar S (eds): Taenia solium Cysticercosis. From Basic to Clinical Science. Oxon, UK: CABI Publishing; 2002: ????-????.
6. Winkler AS. Neurocysticercosis in sub-Saharan Africa: a review of prevalence, clinical characteristics, diagnosis, and management. Pathog Glob Health 2012; 106: 261-274.
7. Garcia HH, Gilman RH, Gonzalez AE, et al. Hyperendemic human and porcine Taenia solium infection in Peru. Am J Trop Med Hyg 2003; 68: 268-275.
8. Schantz PM, Moore AC, Munoz JL, et al. Neurocysticercosis in an Orthodox Jewish community in New York City. N Engl J Med 1992; 327: 692-695.
9. Rajkotia Y, Lescano AG, Gilman RH, Cornejo C & Garcia HH. Economic burden of neurocysticercosis: results from Peru. Trans R Soc Trop Med Hyg 2007; 101: 840-846.
10. Praet N, Speybroeck N, Manzanedo R, et al. The disease burden of Taenia solium cysticercosis in Cameroon. PLoS Negl Trop Dis 2009; 3: e406.
11. Croker C, Reporter R & Mascola L. Use of statewide hospital discharge data to evaluate the economic burden of neurocysticercosis in Los Angeles County (1991-2008). Am J Trop Med Hyg 2010; 83: 106-110.
12. Jeon HK, Kim KH, Chai JY, Yang HJ, Rim HJ & Eom KS. Sympatric distribution of three human Taenia tapeworms collected between 1935 and 2005 in Korea. Korean J Parasitol 2008; 46: 235-241.
13. Anantaphruti MT, Yamasaki H, Nakao M, et al. Sympatric occurrence of Taenia solium, T. saginata, and T. asiatica, Thailand. Emerg Infect Dis 2007; 13: 1413-1416.
14. Conlan JV, Vongxay K, Fenwick S, Blacksell SD & Thompson RC. Does interspecific competition have a moderating effect on Taenia solium transmission dynamics in Southeast Asia? Trends Parasitol 2009; 25: 398-403.
15. Garcia HH, Gonzalez AE, Gilman RH & for The Cysticercosis Working Group in Peru. Diagnosis, treatment and control of Taenia solium cysticercosis. Curr Opin Infect Dis 2003; 16: 411-419.
16. Newton CR & Garcia HH. Epilepsy in poor regions of the world. Lancet 2012; 380: 1193-1201.
17. Ndimubanzi PC, Carabin H, Budke CM, et al. A systematic review of the frequency of neurocysticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis 2010; 4: e870.
18. Chopra JS, Kaur U & Mahajan RC. Cysticerciasis and epilepsy: a clinical and serological study. Trans R Soc Trop Med Hyg 1981; 75: 518-520.
19. Garcia HH, Gilman R, Martinez M, et al. Cysticercosis as a major cause of epilepsy in Peru. The Cysticercosis Working Group in Peru (CWG). Lancet 1993; 341: 197-200.
20. Rottbeck R, Nshimiyimana JF, Tugirimana P, et al. High prevalence of cysticercosis in people with epilepsy in southern Rwanda. PLoS Negl Trop Dis 2013; 7: e2558.
21. Winkler AS, Blocher J, Auer H, Gotwald T, Matuja W & Schmutzhard E. Epilepsy and neurocysticercosis in rural Tanzania-An imaging study. Epilepsia 2009; 50: 987-993.
22. Singh G, Bawa J, Chinna D, et al. Association between epilepsy and cysticercosis and toxocariasis: a population-based case-control study in a slum in India. Epilepsia 2012; 53: 2203-2208.
23. Quet F, Guerchet M, Pion SD, Ngoungou EB, Nicoletti A & Preux PM. Meta-analysis of the association between cysticercosis and epilepsy in Africa. Epilepsia 2010; 51: 830-837.
24. Del Brutto OH & Garcia HH. Cysticercosis of the Human Nervous System. Viena, Springer, 2014: 135.
25. Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004; 350: 249-258.
26. Escobar A. The pathology of neurocysticercosis. In Palacios E, Rodriguez-Carbajal J & Taveras JM (eds): Cysticercosis of the Central Nervous System. Springfield, Charles C. Thomas, 1983: 27-54.
27. Garcia HH, Gonzalez AE, Rodriguez S, et al. Neurocysticercosis: unraveling the nature of the single cysticercal granuloma. Neurology 2010; 75: 654-658.
28. Bickerstaff ER, Cloake PCP, Hughes B & Smith WT. The racemose form of cerebral cysticercosis. Brain 1952; 75: 1-16.
29. Bandres JC, White AC Jr, Samo T, Murphy EC & Harris RL. Extraparenchymal neurocysticercosis: report of five cases and review of management. Clin Infect Dis 1992; 15: 799-811.
30. Fleury A, Carrillo-Mezo R, Flisser A, Sciutto E & Corona T. Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Rev Anti Infect Ther 2011; 9: 123-133.
31. Tsang V & Wilson M. Taenia solium cysticercosis, an under-recognized but serious public health problem. Parasitol Today 1995; 11, 124-126.
32. Garcia HH, Gonzalez AE, Gilman RH, et al. Short report: transient antibody response in Taenia solium infection in field conditions-a major contributor to high seroprevalence. Am J Trop Med Hyg 2001; 65: 31-32.
33. Mwape KE, Phiri IK, Praet N, et al. The incidence of human cysticercosis in a rural community of Eastern Zambia. PLoS Negl Trop Dis 2013; 7: e2142.
34. Meza-Lucas A, Carmona-Miranda L, Garcia-Jeronimo RC, et al. Short report: limited and short-lasting humoral response in Taenia solium: seropositive households compared with patients with neurocysticercosis. Am J Trop Med Hyg 2003; 69: 223-227.
35. Verastegui M, Gilman RH, Gonzales A, et al. Taenia solium oncosphere antigens induce immunity in pigs against experimental cysticercosis. Vet Parasitol 2002; 108: 49-62.
36. de Aluja AS, Martinez MJ & Villalobos AN. Taenia solium cysticercosis in young pigs: age at first infection and histological characteristics. Vet Parasitol 1998; 76: 71-79.
37. Garcia-Noval J, Allan JC, Fletes C, et al. Epidemiology of Taenia solium taeniasis and cysticercosis in two rural Guatemalan communities. Am J Trop Med Hyg 1996; 55: 282-289.
38. Sanchez AL, Lindback J, Schantz PM, et al. A population-based, case-control study of Taenia solium taeniasis and cysticercosis. Ann Trop Med Parasitol 1999; 93: 247-258.
39. Fleury A, Gomez T, Alvarez I, et al. High prevalence of calcified silent neurocysticercosis in a rural village of Mexico. Neuroepidemiology 2003; 22: 139-145.
40. Montano SM, Villaran MV, Ylquimiche L, et al. Neurocysticercosis: association between seizures, serology, and brain CT in rural Peru. Neurology 2005; 65: 229-233.
41. Del Brutto OH, Santibanez R, Idrovo L, et al. Epilepsy and neurocysticercosis in Atahualpa: a door-to-door survey in rural coastal Ecuador. Epilepsia 2005; 46: 583-587.
42. Prasad A, Gupta RK, Pradhan S, Tripathi M, Pandey CM & Prasad KN. What triggers seizures in neurocysticercosis? A MRI-based study in pig farming community from a district of North India. Parasitol Int 2008; 57: 166-171.
43. Henneberg R. Die tierischen parasiten des zentralnervensystem. In Lewandowsky M (ed.): Handbuch der Neurologie. Berlin, Verlag Von Julius Springer, 1912: 643-712.
44. McArthur WP. Cysticercosis as seen in the British army with special reference to the production of epilepsy. Trans R Soc Trop Med Hyg 1934; 27: 343-363.
45. Dixon HB & Lipscomb FM. ??????. In Office HMsS (ed.): Cysticercosis: An Analysis and Follow-up of 450 Cases. London: Medical Research Council; 1961: 58 p.
46. Rodriguez S, Wilkins P & Dorny P. Immunological and molecular diagnosis of cysticercosis. Pathog Glob Health 2012; 106: 286-298.
47. Wilson M, Bryan RT, Fried JA, et al. Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis 1991; 164: 1007-1009.
48. Zini D, Farrell VJ & Wadee AA. The relationship of antibody levels to the clinical spectrum of human neurocysticercosis. J Neurol Neurosurg Psychiatry 1990; 53: 656-661.
49. Khan NA & Sotelo J. Presentation of a membrane cysticercus antigen and its homology with excretory-secretory antigen. Acta Leiden 1989; 57: 123-129.
50. Evans CA, Garcia HH, Hartnell A, et al. Elevated concentrations of eotaxin and interleukin-5 in human neurocysticercosis. Infect Immun 1998; 66: 4522-4525.
51. Sciutto E, Chavarria A, Fragoso G, Fleury A & Larralde C. The immune response in Taenia solium cysticercosis: protection and injury. Parasite Immunol 2007; 29: 621-636.
52. Damian RT. The exploitation of host immune responses by parasites. J Parasitol 1987; 73: 3-13.
53. Correa D, Dalma D, Espinoza B, et al. Heterogeneity of humoral immune components in human cysticercosis. J Parasitol 1985; 71: 535-541.
54. Flisser A. Taenia solium cysticercosis: some mechanisms of parasite survival in immunocompetent hosts. Acta Leiden 1989; 57: 259-263.
55. Willms K. Morphology and biochemistry of the pork tapeworm, Taenia solium. Curr Top Med Chem 2008; 8: 375-382.
56. Alvarez JI, Colegial CH, Castano CA, Trujillo J, Teale JM & Restrepo BI. The human nervous tissue in proximity to granulomatous lesions induced by Taenia solium metacestodes displays an active response. J Neuroimmunol 2002; 127: 139-144.
57. Bueno EC, dos Ramos Machado L, Livramento JA & Vaz AJ. Cellular immune response of patients with neurocysticercosis (inflammatory and non-inflammatory phases). Acta Trop 2004; 91: 205-213.
58. Chavarria A, Roger B, Fragoso G, et al. TH2 profile in asymptomatic Taenia solium human neurocysticercosis. Microbes Infect 2003; 5: 1109-1115.
59. Restrepo BI, Aguilar MI, Melby PC & Teale JM. Analysis of the peripheral immune response in patients with neurocysticercosis: evidence for T cell reactivity to parasite glycoprotein and vesicular fluid antigens. Am J Trop Med Hyg 2001; 65: 366-370.
60. Rodriguez-Sosa M, David JR, Bojalil R, Satoskar AR & Terrazas LI. Cutting edge: susceptibility to the larval stage of the helminth parasite Taenia crassiceps is mediated by Th2 response induced via STAT6 signaling. J Immunol 2002; 168: 3135-3139.
61. Terrazas LI, Bojalil R, Govezensky T & Larralde C. Shift from an early protective Th1-type immune response to a late permissive Th2-type response in murine cysticercosis (Taenia crassiceps). J Parasitol 1998; 84: 74-81.
62. Villa OF & Kuhn RE. Mice infected with the larvae of Taenia crassiceps exhibit a Th2-like immune response with concomitant anergy and downregulation of Th1- associated phenomena. Parasitology 1996; 112(Pt 6): 561-570.
63. Toenjes SA & Kuhn RE. The initial immune response during experimental cysticercosis is of the mixed Th1/Th2 type. Parasitol Res 2003; 89: 407-413.
64. Diaz MA, Villalobos N, de Aluja A, et al. Th1 and Th2 indices of the immune response in pigs vaccinated against Taenia solium cysticercosis suggest various host immune strategies against the parasite. Vet Immunol Immunopathol 2003; 93: 81-90.
65. Amit P, Prasad KN, Kumar GR, et al. Immune response to different fractions of Taenia solium cyst fluid antigens in patients with neurocysticercosis. Exp Parasitol 2011; 127: 687-692.
66. Kashyap B, Das S, Jain S, Agarwal A, Kaushik JS & Kaur IR. Correlation between the clinico radiological heterogeneity and the immune-inflammatory profiles in pediatric patients with neurocysticercosis from a tertiary referral centre. J Trop Pediatr 2012; 58: 320-323.
67. Chavarria A, Fleury A, Bobes RJ, Morales J, Fragoso G & Sciutto E. A depressed peripheral cellular immune response is related to symptomatic neurocysticercosis. Microbes Infect 2006; 8: 1082-1089.
68. Pearce EJ, Caspar P, Grzych JM, Lewis FA & Sher A. Pillars article: downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med 1991: 173: 159-166. J Immunol 2012; 189: 1104-1111.
69. Vuitton DA & Gottstein B. Echinococcus multilocularis and its intermediate host: a model of parasite-host interplay. J Biomed Biotechnol 2010; 2010: 923193.
70. Wang IC, Fan PC, Lu SC, Fan CK & Su KE. Suppression of host Th1-type granulomatous inflammation by Taenia solium metacestodes is related to down-regulation of osteopontin gene expression. Int J Parasitol 2008; 38: 239-248.
71. Cardenas G, Valdez R, Saenz B, et al. Impact of Taenia solium neurocysticercosis upon endocrine status and its relation with immuno-inflammatory parameters. Int J Parasitol 2012; 42: 171-176.
72. Adalid-Peralta L, Fleury A, Garcia-Ibarra T, et al. Human neurocysticercosis: in vivo expansion of peripheral regulatory T cells and their recruitment in the central nervous system. J Parasitol 2012; 98: 142-148.
73. Gundra UM, Mishra BB, Wong K & Teale JM. Increased disease severity of parasite-infected TLR2-/- mice is correlated with decreased central nervous system inflammation and reduced numbers of cells with alternatively activated macrophage phenotypes in a murine model of neurocysticercosis. Infect Immun 2011; 79: 2586-2596.
74. Terrazas LI, Montero D, Terrazas CA, Reyes JL & Rodriguez-Sosa M. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis. Int J Parasitol 2005; 35: 1349-1358.
75. Guerra-Giraldez C, Marzal M, Cangalaya C, et al. Disruption of the blood-brain barrier in pigs naturally infected with Taenia solium, untreated and after anthelmintic treatment. Exp Parasitol 2013; 134: 443-446.
76. White AC Jr, Robinson P & Kuhn R. Taenia solium cysticercosis: host-parasite interactions and the immune response. Chem Immunol 1997; 66: 209-230.
77. Nash TE, Singh G, White AC, et al. Treatment of neurocysticercosis: current status and future research needs. Neurology 2006; 67: 1120-1127.
78. Mishra BB, Gundra UM, Wong K & Teale JM. MyD88-deficient mice exhibit decreased parasite-induced immune responses but reduced disease severity in a murine model of neurocysticercosis. Infect Immun 2009; 77: 5369-5379.
79. Uddin J, Gonzalez AE, Gilman RH, et al. Neurocysticercal antigens stimulate chemokine secretion from human monocytes via an NF-kappaB-dependent pathway. Microbes Infect 2006; 8: 1732-1740.
80. Uddin J, Garcia HH, Gilman RH, Gonzalez AE & Friedland JS. Monocyte-astrocyte networks and the regulation of chemokine secretion in neurocysticercosis. J Immunol 2005; 175: 3273-3281.
81. Patil S, Robinson P, Actor JK, Baig S & White AC Jr. Proinflammatory cytokines in granulomas associated with murine cysticercosis are not the cause of seizures. J Parasitol 2006; 92: 738-741.
82. Prasad A, Prasad KN, Gupta RK & Pradhan S. Increased expression of ICAM-1 among symptomatic neurocysticercosis. J Neuroimmunol 2009; 206: 118-120.
83. Verma A, Prasad KN, Cheekatla SS, Nyati KK, Paliwal VK & Gupta RK. Immune response in symptomatic and asymptomatic neurocysticercosis. Med Microbiol Immunol 2011; 200: 255-261.
84. Parks WC, Wilson CL & Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617-629.
85. Alvarez JI & Teale JM. Differential changes in junctional complex proteins suggest the ependymal lining as the main source of leukocyte infiltration into ventricles in murine neurocysticercosis. J Neuroimmunol 2007; 187: 102-113.
86. Alvarez JI & Teale JM. Multiple expression of matrix metalloproteinases in murine neurocysticercosis: implications for leukocyte migration through multiple central nervous system barriers. Brain Res 2008; 1214: 145-158.
87. Verma A, Prasad KN, Nyati KK, et al. Association of MMP-2 and MMP-9 with clinical outcome of neurocysticercosis. Parasitology 2011; 138: 1423-1428.
88. Gupta RK, Awasthi R, Garg RK, et al. T1-weighted dynamic contrast-enhanced MR evaluation of different stages of neurocysticercosis and its relationship with serum MMP-9 expression. AJNR Am J Neuroradiol 2013; 34: 997-1003.
89. Alvarez JI, Krishnamurthy J & Teale JM. Doxycycline treatment decreases morbidity and mortality of murine neurocysticercosis: evidence for reduction of apoptosis and matrix metalloproteinase activity. Am J Pathol 2009; 175: 685-695.
90. Uddin J, Gonzalez AE, Gilman RH, et al. Mechanisms regulating monocyte CXCL8 secretion in neurocysticercosis and the effect of antiparasitic therapy. J Immunol 2010; 185: 4478-4484.
91. Serpa JA, Moran A, Goodman JC, Giordano TP & White AC Jr. Neurocysticercosis in the HIV era: a case report and review of the literature. Am J Trop Med Hyg 2007; 77: 113-117.
92. Soto Hernandez JL, Ostrosky Zeichner L, Tavera G & Gomez Avina A. Neurocysticercosis and HIV infection: report of two cases and review. Surg Neurol 1996; 45: 57-61.
93. Delobel P, Signate A, El Guedj M, et al. Unusual form of neurocysticercosis associated with HIV infection. Eur J Neurol 2004; 11: 55-58.
94. Ramos JM, Masia M, Padilla S, Bernal E, Martin-Hidalgo A & Gutierrez F. Fatal infection due to larval cysts of cestodes (neurocysticercosis and hydatid disease) in human immunodeficiency virus (HIV) infected patients in Spain: report of two cases. Scand J Infect Dis 2007; 39: 719-723.
95. Handique SK, Das RR, Saharia B, Das P, Buragohain R & Saikia P. Coinfection of Japanese encephalitis with neurocysticercosis: an imaging study. AJNR Am J Neuroradiol 2008; 29: 170-175.
96. Singh P, Kalra N, Ratho RK, Shankar S, Khandelwal N & Suri S. Coexistent neurocysticercosis and Japanese B encephalitis: MR imaging correlation. AJNR Am J Neuroradiol 2001; 22: 1131-1136.
97. Das SK, Nityanand S, Sood K, et al. Japanese B encephalitis with neurocysticercosis. J Assoc Physicians India 1991; 39: 643-644.
98. Allan JC, Avila G, Garcia Noval J, Flisser A & Craig PS. Immunodiagnosis of taeniasis by coproantigen detection. Parasitology 1990; 3: 473-477.
99. Gilman RH, Del Brutto OH, Garcia HH & Martinez M. Prevalence of taeniosis among patients with neurocysticercosis is related to severity of infection. The Cysticercosis Working Group in Peru. Neurology 2000; 55: 1062.
100. Dixon HBF & Hargreaves WH. Cysticercosis (Taenia solium): a further ten years' clinical study, covering 284 cases. Q J Med 1944; 13: 107-121.
101. Allan JC, Velasquez-Tohom M, Garcia-Noval J, et al. Epidemiology of intestinal taeniasis in four, rural, Guatemalan communities. Ann Trop Med Parasitol 1996; 90: 157-165.
102. Lescano AG, Garcia HH, Gilman RH, et al. Taenia solium cysticercosis hotspots surrounding tapeworm carriers: clustering on human seroprevalence but not on seizures. PLoS Negl Trop Dis 2009; 3: e371.
103. Flisser A, Viniegra AE, Aguilar-Vega L, Garza-Rodriguez A, Maravilla P & Avila G. Portrait of human tapeworms. J Parasitol 2004; 90: 914-916.
104. Mendlovic F, Carrillo-Farga J, Torres J, Laclette JP & Flisser A. Differential expression of calreticulin in developmental stages of Taenia solium. J Parasitol 2006; 92: 789-795.
105. Leon-Cabrera S, Cruz-Rivera M, Mendlovic F, et al. Standardization of an experimental model of human taeniosis for oral vaccination. Methods 2009; 49: 346-350.
106. Leon-Cabrera S, Cruz-Rivera M, Mendlovic F, et al. Immunological mechanisms involved in the protection against intestinal taeniosis elicited by oral immunization with Taenia solium calreticulin. Exp Parasitol 2012; 132: 334-340.
107. Zhang W & McManus DP. Vaccination of dogs against Echinococcus granulosus: a means to control hydatid disease? Trends Parasitol 2008; 24: 419-424.
108. Zhang W, Zhang Z, Shi B, et al. Vaccination of dogs against Echinococcus granulosus, the cause of cystic hydatid disease in humans. J Infect Dis 2006; 194: 966-974.
109. Petavy AF, Hormaeche C, Lahmar S, et al. An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease: a pilot study. PLoS Negl Trop Dis 2008; 2: e125.